In an article on INC42, Partnerships are important strategic moves by businesses aimed at gaining a competitive in a given market segment. However, the choice for a partner should be made carefully in order for the company to enjoy the targeted advantages. Foresite Capital, under the leadership of its founder and managing director Dr. Jim Tananbaum made such a strategic move in April 2017. The company appointed an experienced former director of Illumina, Dr. Molly He. With over 15 years of experience as a research scientists and several patents and publications to her name, Dr. He was strategically appointed as a venture partner to help the company break into new areas and diversify its portfolio. The company hopes that Dr. He’s education, skills and leadership experience working in the pharmaceutical industry will enable the company venture into next-generation sequencing portfolio. It is projected that the new portfolio will become an important component in drug development and clinical research.
Career and Education History
Jim Tananbaum is not only an investor in the field of medicine but also a scholar. He is an alumnus of some the best universities in the world. He holds a Doctor of Medicine (M.D.) from the prestigious Harvard Medical School. He also graduated from Yale with a Bachelor of Science and a Bachelor of Science in Electrical Engineering degrees. Other working as the chief executive officer and managing director of his San Francisco-based company, Dr. Tananbaum has also served as a company management executive for GelTex Pharmaceuticals and Theravance. He was appointed on several boards at Harvard and Yale universities. You can visit Insider Monkey for more details.
Jim Tananbaum is a serial investor who has founded and invested in several companies. Other than Foresite Capital, he has successfully invested in over 20 companies specializing in pharmaceutical and healthcare products and services. His investment portfolio includes Amerigroup, Jazz Pharmaceuticals and Amira Pharmaceuticals. The success of the latter attracted the interest of Bristol-Meyers Squibb, which later acquired. Similarly, Genzyme acquired Geltex Pharmaceuticals, which Dr. Tananbaum founded in a deal worth $1.6 billion. His current creation, Foresite Capital, specializes in identifying and financially aiding emerging companies in the healthcare sector with unique products that can transform the sector. More details can be found on LinkedIn.